Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

247 views

Visitors from

US 53%·

AU 33%·

IN 7%·

GB 2%·

FR 1%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Viatris' Q1 2026 Earnings: What to Expect

April 23, 2026 at 08:03 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) operates as a healthcare company in North America and internationally. Valued at a market cap of $16.9 billion, the company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. VTRS is expected to release its Q1 2026 earnings on Thursday, May 7, after the market closes.

Ahead of the event, analysts expect the company’s EPS to be $0.52 on a diluted basis, up 4% from $0.50 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

For fiscal 2026, analysts project the company’s EPS to be $2.44, up 3.8% from $2.35 in fiscal 2025. Moreover, its EPS is expected to rise by roughly 7.4% year over year (YoY) to $2.62 in fiscal 2027.

VTRS stock has surged 88.8% over the past 52 weeks, outperforming the S&P 500 Index’s ($SPX) 35% rise and the State Street Healthcare Select Sector SPDR ETF’s (XLV) 8.4% rise during the same time frame.

On Feb. 2, VTRS stock declined 5.2% following the release of its Q4 2025 earnings. The company’s revenue for the quarter amounted to $3.7 billion, surpassing Wall Street’s forecasts. Moreover, its adjusted EPS came in at $0.57, also coming in on top of the Street’s expectations. Viatris expects full-year earnings of $2.33 to $2.47 per share and revenue of $14.45 to $14.95 billion.

Analysts are somewhat bullish on VTRS, with the stock having a “Moderate Buy” rating overall. Among the 10 analysts covering the stock, five are recommending a “Strong Buy,” four suggest a “Hold,” and one suggests a “Moderate Sell.” VTRS’ average analyst price target is $15.78, indicating an upside of 8.7% from the current levels.

On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article